- Home
- EWCZ vs SGMT Comparison
EWCZ vs SGMT Comparison
Compare EWCZ & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- SGMT
- Stock Information
- Founded
- EWCZ 2004
- SGMT 2006
- Country
- EWCZ United States
- SGMT United States
- Employees
- EWCZ N/A
- SGMT N/A
- Industry
- EWCZ Package Goods/Cosmetics
- SGMT
- Sector
- EWCZ Consumer Discretionary
- SGMT
- Exchange
- EWCZ Nasdaq
- SGMT Nasdaq
- Market Cap
- EWCZ 239.2M
- SGMT 269.2M
- IPO Year
- EWCZ 2021
- SGMT 2023
- Fundamental
- Price
- EWCZ $4.77
- SGMT $7.11
- Analyst Decision
- EWCZ Buy
- SGMT Strong Buy
- Analyst Count
- EWCZ 7
- SGMT 8
- Target Price
- EWCZ $5.86
- SGMT $27.25
- AVG Volume (30 Days)
- EWCZ 512.8K
- SGMT 711.2K
- Earning Date
- EWCZ 08-13-2025
- SGMT 08-13-2025
- Dividend Yield
- EWCZ N/A
- SGMT N/A
- EPS Growth
- EWCZ N/A
- SGMT N/A
- EPS
- EWCZ 0.20
- SGMT N/A
- Revenue
- EWCZ $212,509,000.00
- SGMT N/A
- Revenue This Year
- EWCZ N/A
- SGMT N/A
- Revenue Next Year
- EWCZ $2.17
- SGMT N/A
- P/E Ratio
- EWCZ $24.00
- SGMT N/A
- Revenue Growth
- EWCZ N/A
- SGMT N/A
- 52 Week Low
- EWCZ $2.72
- SGMT $1.73
- 52 Week High
- EWCZ $8.91
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- EWCZ 51.92
- SGMT 37.61
- Support Level
- EWCZ $4.29
- SGMT $6.53
- Resistance Level
- EWCZ $4.82
- SGMT $10.06
- Average True Range (ATR)
- EWCZ 0.28
- SGMT 0.70
- MACD
- EWCZ 0.06
- SGMT -0.26
- Stochastic Oscillator
- EWCZ 66.51
- SGMT 16.37
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.